Clinical trial · Observational
COVID-19 Epidemic and Patients With Myeloproliferative Neoplasias
Observational Study of the Impact of the COronaVirus Disease 2019 (COVID-19) Epidemic on Patients With Myeloproliferative Neoplasias
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The classic myeloproliferative neoplasias (MNP), including polycythemia vera (PV), essential thrombocythemia (ET), primary myelofibrosis (PMF) or secondary to PV or ET, are among the most frequent of malignant hemopathies, with overall prevalence estimated at around 10,000 patients followed in France. Due to the median age of patients around 65, the frequency of cardiovascular complications of these thrombogenic diseases and the impact of cytoreductive treatments on immune cells, these patients are considered to be at risk of developing forms severe of COVID-19. This study will assess the impact of MNPs on the risk of developing a severe form of COVID-19, identify new risk factors linked to the disease as well as the impact of treatments for MNPs according to their pharmacological class.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| COVID-19 Infection | — | UNRESOLVED | — |
| Myeloproliferative Neoplasm | Myeloproliferative Neoplasm | CURATED_BROADER | 0.80 |
Interventions
Interventions (0)
Data not yet available
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (4)
- measure
- Rate of serious coronavirus infection in different MNP patient subgroups
- timeFrame
- Through inclusion period, an average of 6 months
- description
- The crude rate of cumulative incidence of serious infection proven to COVID-19, compared to the population of the same age, same sex, same region of residence during the epidemic period.
- measure
- Proportion of MNP patients who had COVID-19 infection during the 2020 epidemic.
- timeFrame
- Through inclusion period, an average of 6 months
- description
- Number of MNP patients who had COVID-19 compared to general population in France
- measure
- Rate of death of MNP patients who had COVID-19
- timeFrame
- Through study completion, an average of 1 year
- description
- Number of MNP patients who died from COVID-19
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Patient with PV, ET, PMF or MF secondary to PV or ET diagnosed before the COVID-19 pandemic * Seen in consultation or teleconsultation from May 2020 or deceased if the investigator became aware of this death during the study period Exclusion Criteria: * Refusal to participate in the study
References
Publications (0)
Data not yet available